CONBA(SH:600572) Ge Long Hui A P P·2026-02-04 09:15Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are aimed at treating diabetic nephropathy [1] Group 1: Company Developments - The full subsidiary of Kang En Bei, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., is responsible for the clinical trial application of TFA003 tablets [1] - TFA003 is classified under Traditional Chinese Medicine categories 2.1 and 2.3, with oral administration as the delivery method [1] Group 2: Clinical Trial Insights - The clinical trial approval indicates that the optimal dosage for TFA003 will be confirmed after the completion of the clinical trials [1] - Preliminary pharmacodynamic and pharmacokinetic animal studies have shown that TFA003 significantly improves renal function indicators in urine and blood, enhances glomerular filtration and tubular reabsorption functions, and improves renal pathological morphology [1] - TFA003 demonstrates potential for development as a new Traditional Chinese Medicine for diabetic nephropathy [1]